The prognostic value of inflammation indexes in esophageal cancer has not been established. Recent studies have shown that the advanced lung cancer inflammation index (ALI) is a useful predictive factor. The purpose of the current study was to determine whether the ALI is useful for predicting long-term survival in patients with esophageal squamous cell carcinoma (ESCC).
Introduction
Esophageal cancer (EC) is the eighth most common cancer worldwide. 1 In the People's Republic of China, EC was the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in 2008. 1 Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of ECs in the People's Republic of China, in contrast to the predominance of esophageal adenocarcinoma in the Western countries. 2, 3 Because there are vital biological differences between ECs in the People's Republic of China and Western countries, a prognostic model that takes into account the predominance of ESCC in the People's Republic of China is necessary for deciding on a postoperative strategy that will prolong the survival. Thus, assessing the prognostic factors in ESCC is more and more important.
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Recently, systemic inflam matory response (SIR) plays a vital role in the progression of cancer. 4, 5 Previous reports have shown that systemic inflammation, indicated by an elevated level of serum C-reactive protein (CRP), strongly influenced the prognosis in patients with gastrointestinal carcinomas. 6 Moreover, the Glasgow prognostic score (GPS), which is based on the serum CRP and hypoalbuminemia, has been demonstrated as an indicator for the prognosis in various types of cancers, including ECs. [7] [8] [9] In addition, there is increasing evidence that neutrophil to lymphocyte ratio (NLR) can be used for prognostication in several types of cancer. 10, 11 Recently, Jafri et al 12 evaluated a novel inflammation-based prognostic system, named advanced lung cancer inflammation index (ALI; based on body mass index, serum albumin [Alb] and NLR). The results showed that ALI was considered as a useful predictive factor in lung cancer. 12 To our knowledge, however, no studies regarding ALI in patients with ECs are available. Therefore, the purpose of the current study was to determine whether the ALI is still useful for predicting long-term survival in patients with ESCC.
Materials and methods
A retrospective analysis was performed on 293 patients with ESCC in our department from January 2006 to December 2008. All patients were diagnosed as ESCC. Patients who had received preoperative neoadjuvant therapy (chemotherapy and/or radiotherapy) were excluded. Based on the medical records, the following data were collected for each patient: age, sex, height, weight, differentiation, tumor length and location, laboratory examination, depth invasion, nodal metastasis, and other miscellaneous characteristics. Ethical approval was obtained from the Ethical Committees of Zhejiang Cancer Hospital. In our institute, the patients were followed up in the outpatient department. Either X-ray or computed tomography of the chest was performed during the follow-up. The cancer-specific survival (CSS) was analyzed in this study. The last follow-up time was November 2011. All patients were staged according to the 7th edition of the American Joint Committee on Cancer Cancer Staging. 13 All of the patients were treated with esophagectomy. The standard surgical approach included the Ivor Lewis and the McKeown procedure. 2 The lymphadenectomy included two-field (thoracoabdominal) and three-field (cervicalthoracoabdominal) lymphadenectomy. Most of the patients underwent two-field lymphadenectomy. Three-field lymphadenectomy was used only if the cervical nodes metastasis.
As the role of postoperative adjuvant chemoradiotherapy was controversial during that period, postoperative adjuvant therapy was not mandatory. Cisplatin and 5-fluorouracil were the most frequent chemotherapy. Postoperative radiation was initially performed through the anteropos terior field to 36 Gy, then through the parallel opposing oblique fields to 14 Gy, in order to avoid the spinal cord.
Statistical analysis
Statistical analysis was conducted with SPSS 17.0 (SPSS Inc., Chicago, IL, USA). The ALI was calculated using the following formula: body mass index (BMI) × Alb/NLR, and it was categorized into two groups: (ALI $18 and ALI ,18). 12 The BMI = body weight (kg)/height 2 (m 2 ), and it was categorized into two groups: (BMI .18.5 kg/m 2 and BMI #18.5 kg/m 2 ).
14 The Alb was categorized into two groups: (Alb .3.5 g/dL and Alb #3.5 g/dL). 15 The NLR was categorized into two groups: (NLR ,5 and NLR $5).
10,11 The Kaplan-Meier method was used to calculate the CSS, and the difference was assessed by the log-rank test. Univariate and multivariate analyses were performed to evaluate the prognostic factors. A P,0.05 was considered to be statistically significant.
Results
Among the 293 patients, there were 34 (11.6%) women and 259 (88.4%) men. The mean age was 59.5±7.9 years (range from 38 to 78 years). There were 120 (41.0%) patients with ALI ,18, and 173 (59.0%) patients with ALI $18.
The relationships between the ALI and clinicopathological characteristics of the 293 patients for ESCC are shown in Table 1 . Our study showed that ALI was significantly higher in patients with large tumors (P=0.028), poor differentiation (P=0.010), deep invasion (P=0.009), and nodal metastasis (P=0.004).
The 5-year CSS was 34.5% in our study. Patients with ALI ,18 had a significantly poor 5-year CSS compared to ALI $18 (21.7% versus 43.4%, P,0.001) (Figure 1) . By univariate analysis, tumor length, vessel involvement, depth invasion, nodal metastasis, BMI, Alb, NLR, and ALI were significant association with the 5-year CSS. On multivariate analysis, we showed that ALI was a significant predictive factor of CSS (P=0.024) ( Table 2) .
Discussion
To our knowledge, this is the first study to show ALI as an independent prognostic factor in patients with ESCC. Our study demonstrated that ALI is still a useful predictive factor for CSS in patients who underwent esophagectomy for ESCC. It has been reported that Alb participate in the SIR. Hypoalbuminemia is a useful prognostic factor for survival in patients with various cancers. Uppal et al 21 reported that preoperative hypoalbuminemia is an independent predictor of poor outcomes in gynecologic cancers. Chandrasinghe et al 22 also showed that hypoalbuminemia predicts poor survival in patients with rectal cancer. In ECs, Ikeda et al 23 demonstrated that hypoalbuminemia was significantly associated with poor survival in EC patients. In addition, recent studies reported that hypoalbuminemia was predictive of the response to adjuvant chemoradiotherapy for EC. 24, 25 In our study, however, hypoalbuminemia was not a significant predictor in patients with ESCC.
NLR is another prognostic factor for survival in various cancers, such as lung cancer, colorectal cancer, and urinary cancer. 26, 27 However, its role in EC is still controversial. Sharaiha et al 10 and Sato et al 11 reported that NLR .5 correlated with poor survival in EC patients. However, Rashid et al 28 and Dutta et al 29 revealed that NLR did not associate with survival in patients with EC. In our study, however, we have demonstrated that BMI, Alb, and NLR did not have prognostic value for patients with ESCC. Thus, we used a new inflammation index, named ALI, based on BMI, Alb and NLR. Our study demonstrated that ALI was a significant predictive factor of CSS (P=0.024).
In conclusion, ALI is still a useful predictive factor in patients with ESCC. ALI is an easy method to assess the systemic inflammation in ESCC patients. High systemic inflammation as judged by ALI ,18 had a significantly poor 5-year CSS compared to ALI $18. However, the prognostic value of the ALI remains to be formally tested within the randomized trials.
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